Here's what we'll cover
Here's what we'll cover
Why Eli Lilly's GLP-1 Cash Matters to Everyday Patients
If you're taking Mounjaro or Wegovy, or you've been considering either, you've probably noticed that the business of GLP-1 medications moves fast. Eli Lilly, the maker of tirzepatide (the active ingredient in Mounjaro and Zepbound), has been channeling enormous profits from its GLP-1 drugs right back into the category. That's not just a Wall Street story. It has direct consequences for whether you can get your medication, what you'll pay, and what new options might be available to you soon.
Understanding where this money is going helps you make smarter decisions about your own treatment path.
Where Eli Lilly Is Putting Its GLP-1 Money
Lilly's GLP-1 franchise generated billions in revenue in 2025, and the company has been transparent about reinvesting a significant portion of those earnings in three main areas.
Manufacturing Expansion
Supply shortages were a defining problem for GLP-1 patients in 2023 and 2024. Lilly has been building out domestic and international manufacturing facilities specifically to meet surging demand for tirzepatide. More production capacity doesn't just mean better availability. It also reduces the conditions that allowed compounding pharmacies to legally produce cheaper alternatives under the FDA's shortage designation.
Pipeline and Formulation R&D
Lilly is also funding development of new GLP-1 formulations, including oral versions of tirzepatide and longer-acting injectable options. Oral GLP-1s could be a major shift for patients who struggle with injections or needle anxiety.
Indication Expansion
Beyond weight loss and type 2 diabetes, tirzepatide is being studied for sleep apnea, heart failure, and metabolic liver disease. Each new approved indication broadens the population of patients who can access the drug with insurance coverage.
What This Means for Drug Availability
The FDA removed tirzepatide from its official drug shortage list in late 2024, which triggered major restrictions on compounded tirzepatide. Lilly's manufacturing investments were central to making that happen.
For patients, this is a double-edged shift. On one hand, commercial supply should be more stable going forward. On the other hand, the cheaper compounded versions that many uninsured or underinsured patients relied on have become harder to access legally.
If you were using a telehealth provider that prescribed compounded tirzepatide, you may have already felt this change. It's worth checking with your provider about your current options and whether brand-name Zepbound or Mounjaro is now accessible through your insurance or a savings program.
How Lilly's Moves Affect the Competitive Landscape
Lilly isn't spending in a vacuum. Novo Nordisk, which makes Ozempic and Wegovy (semaglutide), is doing the same. Meanwhile, a wave of smaller biotechs and pharmaceutical companies are working to bring new GLP-1 and GLP-1 adjacent drugs to market.
This competition matters enormously for pricing. Right now, branded GLP-1 medications without insurance can cost $900 to $1,400 per month. That's not sustainable for most patients, and both companies know it.
As new competitors enter the space and oral formulations launch, pricing pressure from within the GLP-1 category is likely to grow. That could eventually benefit patients, particularly those without strong insurance coverage.
The Compounding Question: Where Things Stand Now
One of the most practically urgent issues for GLP-1 patients is the ongoing legal and regulatory battle over compounded semaglutide and tirzepatide.
Compounded versions of these drugs, made by state-licensed compounding pharmacies or 503B outsourcing facilities, were widely available while the FDA listed them as in shortage. With tirzepatide off the shortage list and compounded semaglutide facing new restrictions following court battles, many patients are navigating a confusing transition.
Here's a quick breakdown of the current status:
If you're currently getting compounded GLP-1 medication, talk to your prescribing provider before your next refill. The regulatory environment is shifting quickly, and your provider should help you understand whether your current source is legally compliant.
What to Ask Your Doctor at Your Next Appointment
Lilly's investments and the broader GLP-1 market shifts create real questions worth bringing to your healthcare provider. Being informed makes that conversation more productive.
Questions worth asking:
- Am I on the right GLP-1 for my situation? Tirzepatide and semaglutide work differently, with tirzepatide targeting both GIP and GLP-1 receptors while semaglutide targets GLP-1 receptors only, and the outcome data differs between them.
- Are there new formulations coming that I should wait for? If oral tirzepatide moves toward approval, that could be meaningful for your adherence and comfort with the injection routine.
- Does my insurance cover Zepbound or Mounjaro? Coverage has been expanding, and your provider's office may be able to assist with prior authorization.
- Are there manufacturer savings programs I qualify for? Both Lilly and Novo Nordisk run copay assistance programs that can dramatically reduce out-of-pocket costs.
- What happens if my compounded prescription is no longer available? Have a backup plan ready before a supply disruption forces an unplanned switch.
Savings Options While the Market Evolves
Waiting for competition to drive prices down isn't a strategy if you need treatment now. There are practical ways to reduce your costs today.
Eli Lilly offers a savings card for Zepbound that, for eligible commercially insured patients, can bring the monthly cost down significantly. The income-based criteria vary, so it's worth checking directly on the Lilly website or through your prescriber.
For those without insurance coverage, GLP-1 Coupons and patient assistance programs remain some of the most reliable tools available. Working with a telehealth provider that specializes in GLP-1 prescriptions can also help you navigate these options without the friction of a traditional office visit.
You can compare the Best Providers on GLP-1.com to find one that fits your budget and access needs.
No waiting list. No insurance needed.
Frequently Asked Questions
Will Eli Lilly's manufacturing investments make tirzepatide easier to get?
Yes, in general terms. Lilly has significantly expanded production capacity for tirzepatide, and the FDA removed it from the official shortage list in late 2024. Availability at retail pharmacies has improved, though individual pharmacy stock can still vary by region.
Why did compounded tirzepatide become harder to get?
When the FDA removes a drug from its shortage list, the legal basis for compounding pharmacies to produce that drug at scale largely disappears. Lilly's expanded supply resolved the shortage designation, which triggered new restrictions on compounded tirzepatide starting in early 2025.
Is tirzepatide better than semaglutide for weight loss?
Clinical trial data suggests tirzepatide produces somewhat greater average weight loss than semaglutide, but individual results vary. Tirzepatide targets two hormone receptors (GIP and GLP-1), while semaglutide targets one. Your doctor can help you decide which is more appropriate based on your health history and goals.
How much does Zepbound cost per month without insurance?
Without insurance, Zepbound typically costs between $1,000 and $1,100 per month for the standard doses. Lilly's savings card program can reduce this substantially for eligible commercially insured patients. Ask your doctor or pharmacist about current programs.
Are oral GLP-1 medications available yet?
An oral form of semaglutide (Rybelsus) is already FDA-approved for type 2 diabetes, though not specifically for weight loss. Eli Lilly and other companies are actively developing oral tirzepatide and other oral GLP-1 options, but these are not yet widely approved for weight management as of mid-2026.
Does insurance cover GLP-1 medications for weight loss?
Coverage varies widely. Many commercial insurance plans cover GLP-1 drugs approved for diabetes (like Mounjaro and Ozempic) more readily than those approved for obesity (like Zepbound and Wegovy). Medicare Part D coverage for weight loss drugs has expanded but still has limitations. Checking directly with your insurer and asking your doctor for prior authorization support is the best approach.
The Bottom Line: What Lilly's GLP-1 Spending Means for Your Treatment
Eli Lilly's ongoing reinvestment in its GLP-1 franchise is fundamentally reshaping the landscape for patients. More manufacturing capacity means fewer shortages. More pipeline investment means new formulations and indications are coming. And more competition, as other players respond, means pricing pressure is building, even if it hasn't fully translated to lower costs at the pharmacy counter yet.
In the short term, you may still face real financial barriers, especially if you're uninsured or underinsured and relied on compounded tirzepatide or semaglutide. That's a genuine hardship, and it's worth being proactive about understanding your options rather than waiting for the market to solve it for you.
In the medium term, the picture looks more encouraging. Oral formulations, broader insurance coverage as more indications are approved, and growing competition from new drug entrants could all help bring costs down within the next two to three years.
What you can control right now is being informed and working with a knowledgeable provider who stays current on this fast-moving space.
Your Next Steps
1. Talk to your doctor or prescriber about which GLP-1 is right for your specific health goals.
2. Check whether your insurance covers Zepbound or Mounjaro, and ask for prior authorization support if needed.
3. Explore savings programs before assuming you can't afford brand-name options.
4. If you're currently on compounded medication, confirm with your provider that your source remains legally compliant.
5. Stay updated as new formulations and competitors reach the market.
GLP-1.com is here to help you navigate all of it. Whether you're just starting to explore your options or trying to reduce what you're paying right now, check out our GLP-1 Coupons page and Provider Comparison Tool to find the path that works for your budget and your health.
As always, consult your physician or a qualified healthcare provider before making any changes to your medication regimen.